Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding (GB:0QOK)
:0QOK
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
8.12Last Year’s EPS
8.47Same Quarter Last Year
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 30, 2025
|% Change Since: -5.25%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Positive
Roche demonstrated strong financial performance in 2024 with significant growth in sales, operating profit, and cash flow. The pharmaceutical and diagnostics divisions both showed robust growth, supported by strategic acquisitions and new product launches. However, challenges such as the decline in COVID-19 sales, impairments affecting net income, and market challenges in China were notable concerns. Overall, the highlights substantially outweigh the lowlights.Company Guidance
During the call, Roche Group provided detailed guidance on its fiscal 2024 performance, highlighting several key metrics. The company achieved an overall group sales growth of 7%, with the base business excluding COVID-19 impacts growing by an impressive 9%. The pharmaceutical division reported a 9% increase, and the diagnostics division saw an 8% rise. Roche confirmed that the final impact of COVID-19 sales reduction was CHF1.1 billion, aligning with their initial guidance. The loss of exclusivity (LOE) impact was CHF1 billion, slightly better than expected. The core operating profit grew by 14%, and the group core operating margin increased by 2.1 percentage points. Additionally, core EPS growth was 12%, excluding tax effects, or 7% when including them. Operating free cash flow surged by 34% to CHF21.2 billion, reflecting strong financial health. Looking forward, Roche anticipates mid-single digit group sales growth and high-single digit core EPS growth for 2025, despite an expected LOE impact of CHF1.2 billion. The company also plans to continue its tradition of increasing dividends, marking the 38th consecutive year of growth in this area.Strong Financial Performance
Group sales grew 7%, with the base business growing 9%, pharma 9%, and diagnostics 8%. Core operating profit increased by 14%, with a core operating margin up 2.1 percentage points. Operating free cash flow increased by 34% to CHF21.2 billion.
Pharmaceutical Achievements
Pharma sales grew 8% to CHF46.2 billion, driven by Vabysmo, Phesgo, and Ocrevus, among others. The company launched two new medicines, PiaSky and Itovebi, in 2024.
Diagnostics Growth
Diagnostics division reported 4% sales growth, with a strong base business growth of 8% driven by immunodiagnostics and clinical chemistry.
Pipeline and Product Launches
Roche achieved several key milestones, including EU approval for Vabysmo pre-filled syringe and positive readouts for trontinemab and NXT007. Launches included Mass Spectrometry system and cobas 6800/8800 version 2.
Strategic Acquisitions and Partnerships
Acquisition of Poseida to expand the allogeneic CAR-T portfolio, introducing potential treatments for oncology and autoimmune diseases.
---
GB:0QOK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0QOK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 30, 2025 | CHF281.70 | CHF283.59 | +0.67% |
| Jul 25, 2024 | CHF272.40 | CHF278.53 | +2.25% |
| Feb 01, 2024 | CHF238.05 | CHF227.58 | -4.40% |
| Jul 27, 2023 | CHF260.25 | CHF260.94 | +0.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Roche Holding (GB:0QOK) report earnings?
Roche Holding (GB:0QOK) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Roche Holding (GB:0QOK) earnings time?
Roche Holding (GB:0QOK) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Roche Holding stock?
The P/E ratio of Roche Holding AG is N/A.
What is GB:0QOK EPS forecast?
GB:0QOK EPS forecast for the fiscal quarter 2024 (Q4) is 8.12.
---